Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN71,9471,952,98
Msft0,13
Nokia4,374,520,65
IBM-1,94
Mercedes-Benz Group AG50,9350,950,39
PFE-3,00
10.05.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 09.05.2025
Genus (GENS.L, London)
Závěr k 9.5.2025 Změna (%) Změna (GBP) Objem obchodů (GBP)
21,10 1,44 0,30 1 186 969
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 11.05.2025
Popis společnosti
Obecné informace
Název společnostiGenus plc
TickerGNS
Kmenové akcie:Ordinary Shares
RICGNS.L
ISINGB0002074580
Poslední známé roční výsledky30.06.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 30.06.2024 3 439
Akcie v oběhu k 30.04.2025 66 036 776
MěnaGBP
Kontaktní informace
UliceMatrix House, Basing View
MěstoBASINGSTOKE
PSČRG21 4DZ
ZeměUnited Kingdom
Kontatní osobaAnand Date
Funkce kontaktní osobyInvestors Relations
Telefon441 256 347 100
Fax441256477385
Kontatní telefon447 815 676 011

Business Summary: Genus plc is a United Kingdom-based animal protein genetics company. The Company supplies breeding animals with desirable characteristics for farmers, enabling them to produce quality meat and milk. Its segments include Genus PIC, Genus ABS and Genus Research and Development. The Genus PIC segment is engaged in the porcine sales business. The Genus ABS segment is engaged in the bovine sales business. Its bovine genetics business sells dairy and beef bull semen and embryos from its superior cattle, which are sold to farmers to breed their cows through artificial insemination. Its porcine genetics business sells genetically superior breeding pigs and semen to farmers, so they can breed commercial pigs with desirable characteristics for pork production. It also provides technical services and advice to farmers, to maximize the performance of its breeding animals in their farms. The Company has supply chain and distribution networks in over 80 countries.
Financial Summary: BRIEF: For the six months ended 31 December 2024, Genus plc revenues increased 1% to L336.4M. Net income decreased 88% to L1.6M. Revenues reflect Operating Genus PIC segment increase of 3% to L181.3M. Net income was offset by Central Cost segment loss increase of 17% to L10.9M. Dividend per share remained flat at L0.10. Basic Earnings per Share excluding Extraordinary Items decreased from L0.21 to L0.02.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSSupport Activities for Animal Production
NAICS2007Research and Development in Biotechnology
NAICS2007Support Activities for Animal Production
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Support Activities for Animal Production
SICCommercial Physical Research
SICLivestock Svcs, Exc. Veterinary



  • Poslední aktualizace: 11.05.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorJorgen Kokke5501.07.202302.05.2023
Chief Financial Officer, Executive DirectorAlison Henriksen-13.01.202013.01.2020
Chief Financial Officer, Executive DirectorAndy Russell-01.08.202501.08.2025
Chief Operating OfficerMatt Culbertson-
Chief Human Resource OfficerAngelle Rosata-01.07.2017
Chief Scientific Officer and Head of Research and DevelopmentElena Rice-
Group General Counsel and Company SecretaryDan Hartley-09.06.201409.06.2014
Chief Operating Officer of Genus ABSJim Low-01.01.2024
Regional Director - ABS EMEAJerry Thompson-01.07.2012